Loading...
Loading...
VIVUS, Inc.
VVUS today announced the U.S. market availability of Qsymia™ (pronounced Kyoo
sim ee' uh). Qsymia is FDA-approved as an adjunct to a reduced-calorie diet
and increased physical activity for chronic weight management in adult
patients with an initial body mass index (BMI) of 30 or greater (obese), or 27
or greater (overweight) in the presence of at least one weight-related
comorbidity, such as hypertension, type 2 diabetes mellitus or high
cholesterol (dyslipidemia). It is the first FDA-approved once daily
combination therapy – and the first new medication available in 13 years – for
the treatment of obesity.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in